ITWs of eureKARE Team
Discover the most dynamic and powerful biotech startup studio in Europe!
eureKARE is the most dynamic and powerful biotech startup studio in Europe. EureKare was launched in July 2021 in Brussels and Paris, backed with 60 millions euros private funding.
eureKARE is a hybrid innovative entity, both an investment firm - not a Venture Capital fund - and an AI-backed startup studio dedicated to propel disruptive biotech startups into the market. With a first round of financing secured at 60 million euros from individual investors and family offices, eureKare focuses on two of the most promising areas in life science: microbiome and synthetic biology.
eureKARE already ambitions to open its equity to investors up to several hundred million.
We can cite two remarkable co-founding investors, Alexandre Mouradian, Chairman at eureKARE, who is at the origin of the Spinoza Foundation, and Alan Howard, co-founder of the British hedge fund Brevan Howard.
These two gentlemen seeded the funding and in less than three months a dozen wealthy families from Switzerland, Germany, UK and USA joined the round table.
eureKARE venture building process is innovative: with the help of its proprietary Artificial Intelligence, the team identifies critical societal problems worth to be solved. Then, the AI searches and identifies the best Academic scientists who could bring a disruptive solution in the areas of microbiome and/or synthetic biology. With the scientist-entrepreneurs joinging the Studio, eureKARE Team commit with them to design & build the solution and co-found the startup together.
For these disruptive startups with high patent potential, eureKARE invests cash from 2 to 4 million over three to four years.
eureKARE is also an investment firm targeting series-B/C growth stage biotech startups. eureKARE invests 3-5 million at once.
For instance, we can cite two amazing startups having eureKARE among their investors:
- eureKARE invested in Coave Therapeutics as part of its €33 million Series B round
- eureKARE invested in DNA Script’s $200 Million Series C Financing
eureKARE objective :
- Founding and investing in 3-5 startups each year
- Investing in 3-5 series-B/C statups each year
ITW Rodolphe Besserve CEO eureKARE
In this new episode, I have the pleasure to welcome Rodolphe Besserve CEO at eureKAR.
In this episode, we talk about Mr. Rodolphe Besserve's path from Chemist Engineer to the Finance World where he was a very succesful professional. Then, we talk about his role, vision and challenges as CEO of eureKARE.
Rodolphe Besserve is a former Managing Director at Société Générale, where he built the Biotech/Medtech activity in ECM and M&A. He conducted more than 50 transnational deals including IPOs, right issues, mergers, LBOs … . Before this, he was an equity analyst covering the healthcare sector. He was ranked #1 research analyst in France in 2010. He is a chemist by training with a master in finance.
At the end of this episode, Mr. Besserve recommanded these books:
ITW Dr. Serge Pampfer CSO eureKARE
In this new episode, I have the pleasure to welcome Dr. Serge Pampfer.
Dr. Pampfer is the former General Director of WBC, a biotech incubator based in Wallonia, Belgium. Prior to that position, Dr. Pampfer was General Manager of GIGA, COO of Beta-Cell and CSO of Arevia. He holds a PhD in cellular biology from the University of Louvain and University of Essen and did his post-doctoral at the Albert Einstein College of Medicine in NYC.
Dr. Pampfer joined eureKare in 2021 as CSO.
In this episode, we talk abtout Dr. Pampfer's path into Science and Science Entrepreneurship. Then, we talk about role as CSO (Chief Scientifc Officer) of eureKARE.
At 9 years-old, the young Serge received this pop-science book "L'aventure de la terre" as a gift. This book was a turning point for him, awaking his researcher mindset and love for Science: https://www.abebooks.fr/LAVENTURE-TERRE-GLOBERAMA-CASTERMAN/30031756317/bd
ITW Dr. Kristin Thompson CBO eureKARE
In this new episode, I have the pleasure to welcome Dr. Kristin Thompson.
Dr. Thompson is an expert in Bio-Pharma Business Development. Former head of strategic partnerships in microbiome at Bioaster, senior BD manager at Famar and BD manager of the French biotech company DaVolterra, she also worked in research at French INSERM and the University of North Carolina, Chapel.
Dr. Thompson holds a PhD in Molecular Medicine from the University of Ulm (Germany).
From basic research to clinical development and pharmaceutical drug manufacturing, having Dr Thompson expertise to back your startup at eureKARE will be precious. And that's why I wanted to discuss with her, to understand better her expertise.
In this episode we talk about Dr. Thompson's path from Academic research to the Bio-Business development. Then we talk about her role and responsabilites as CBO (Chief Business Officer) at eureKARE.
Dr. Thompson recommanded this book "Mountains Beyond Mountains: The Quest of Dr. Paul Farmer, a Man Who Would Cure the World" by Tracy Kidder https://www.amazon.com/Mountains-Beyond-Farmer-Random-Readers/dp/0812980557
ITW Michelle Wilson-André Head of Communications eureKARE
In this new episode, I had the pleasure to welcome Michelle Wilson-André.
Prior to joining eureKARE, Michelle worked in communications and project management roles at science and health focused organisations for over 10 years. She has carried out work in Canada, Spain, and France’s public and private sectors, including at: the Discovery Channel, Ontario Brain Institute, Paris Brain Institute, Cellectis, and France’s national research center (CNRS). Her background spans life sciences (BSc.Dalhousie, University); science and medical communications (MSc. Pompeu Fabra University); and health policy and management (Executive Masters, Sciences Po).
We talk about Michelle's path from Science to Science Communication. Then we talk about her role as Head of Communications at eureKARE.
E² - Épistémê Entrepreneur